Prohibits substitution of prescribed epilepsy drugs by pharmacists without prior notification to and written consent of physician and patient.

This bill prohibits pharmacists from substituting any prescribed anti-epileptic drug (brand or generic) for seizure treatment without first obtaining written consent from both the prescribing physician and the patient (or their parent/guardian/spouse). It directly affects epilepsy patients and their healthcare providers by requiring explicit agreement before any medication change. The key mechanism mandates prior notification and signed consent for substitutions, addressing risks that small formulation differences can cause dangerous toxicity or seizure recurrence. The bill aims to ensure medication stability for a condition where precise dosing is critical, as noted in its rationale.